<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00416429</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000468571</org_study_id>
    <secondary_id>LEONB-PERCY-QUATTRO</secondary_id>
    <secondary_id>EU-20605</secondary_id>
    <secondary_id>LEONB-ET99-058</secondary_id>
    <secondary_id>ROCHE-LEONB-PERCY-QUATTRO</secondary_id>
    <secondary_id>CHIRON-LEONB-PERCY-QUATTRO</secondary_id>
    <nct_id>NCT00416429</nct_id>
  </id_info>
  <brief_title>Medroxyprogesterone or Interferon and/or Aldesleukin in Treating Patients With Metastatic Kidney Cancer</brief_title>
  <official_title>Medroxyprogesterone, Interferon Alpha-2a, Interleukin 2 or Combination of Both Cytokines in Patients With Metastatic Renal Carcinoma of Intermediate Prognosis [PERCY QUATTRO]</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Leon Berard</source>
  <brief_summary>
    <textblock>
      RATIONALE: Medroxyprogesterone may help shrink or slow the growth of kidney cancer.&#xD;
      Interferon may interfere with the growth of tumor cells. Aldesleukin may stimulate white&#xD;
      blood cells to kill tumor cells. It is not yet known whether giving medroxyprogesterone,&#xD;
      interferon, or aldesleukin alone is more effective than giving interferon together with&#xD;
      aldesleukin in treating kidney cancer.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying medroxyprogesterone, interferon, or&#xD;
      aldesleukin to see how well they work when given alone compared to interferon combined with&#xD;
      aldesleukin in treating patients with metastatic kidney cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the overall survival of patients with metastatic renal cell adenocarcinoma&#xD;
           treated with medroxyprogesterone vs recombinant interferon alfa-2a and/or aldesleukin.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the objective response rate (complete and partial) of patients treated with&#xD;
           these regimens.&#xD;
&#xD;
        -  Determine the progression-free survival of patients treated with these regimens.&#xD;
&#xD;
        -  Determine the toxicity of these regimens in these patients.&#xD;
&#xD;
        -  Evaluate the quality of life of patients before and after induction treatment with these&#xD;
           regimens (week 10).&#xD;
&#xD;
      OUTLINE: This is a randomized, controlled, open-label, multicenter study. Patients are&#xD;
      randomized to 1 of 4 treatment arms.&#xD;
&#xD;
        -  Arm I (medroxyprogesterone): Patients receive oral medroxyprogesterone once daily for 12&#xD;
           weeks. Patients may receive a second 12-week course in the presence of responding or&#xD;
           stable disease. Quality of life is assessed at baseline and at weeks 12 and 24.&#xD;
&#xD;
        -  Arm II (recombinant interferon alfa-2a): Patients receive recombinant interferon alfa-2a&#xD;
           subcutaneously (SC) 3 times weekly for 12 weeks. Patients may receive a second 12-week&#xD;
           course in the presence of responding or stable disease. Quality of life is assessed as&#xD;
           in arm I.&#xD;
&#xD;
        -  Arm III (aldesleukin): Patients receive aldesleukin SC twice daily on days 1-5, 8, 9,&#xD;
           15, 16, 22, and 23 and once daily on days 10-12, 17-19, and 24-26. Courses repeat&#xD;
           beginning in weeks 6, 13, and 20. Quality of life is assessed at baseline and at weeks&#xD;
           10 and 24.&#xD;
&#xD;
        -  Arm IV (recombinant interferon alfa-2a and aldesleukin): Patients receive recombinant&#xD;
           interferon alfa-2a as in arm II and receive aldesleukin as in arm III. Quality of life&#xD;
           is assessed as in arm III.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for 5 years and then&#xD;
      annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 456 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">February 2005</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (complete and partial)</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life in week 10</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">456</enrollment>
  <condition>Kidney Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>aldesleukin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alpha-2a</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>medroxyprogesterone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed metastatic renal cell adenocarcinoma, meeting 1 of the&#xD;
             following criteria:&#xD;
&#xD;
               -  More than 1 metastatic site and good performance status (Karnofsky score 80-100%)&#xD;
&#xD;
               -  Sole metastatic site with Karnofsky score = 80%&#xD;
&#xD;
                    -  Karnofsky 90% or 100% not eligible&#xD;
&#xD;
               -  No combination of several metastatic sites and liver metastases and a time&#xD;
                  interval from primary tumor to metastases of &lt; 1 year&#xD;
&#xD;
          -  Nonmeasurable disease and/or few numbers of lesions must be confirmed histologically&#xD;
             and as progressive disease&#xD;
&#xD;
          -  The following metastases are allowed:&#xD;
&#xD;
               -  Lung with or without mediastinum lymph nodes&#xD;
&#xD;
               -  Bone&#xD;
&#xD;
               -  Pleura (solid or liquid with positive cytology)&#xD;
&#xD;
               -  Thoracic lymph nodes&#xD;
&#xD;
               -  Abdominal lymph nodes&#xD;
&#xD;
               -  Superficial lymph nodes&#xD;
&#xD;
               -  Liver&#xD;
&#xD;
               -  Subcutaneous skin/tissue&#xD;
&#xD;
               -  Contralateral kidney&#xD;
&#xD;
               -  Nephrectomy site&#xD;
&#xD;
               -  Other organs&#xD;
&#xD;
          -  Prior metastases allowed provided the following criteria are met:&#xD;
&#xD;
               -  Evidence of progressive disease within the past 3 months&#xD;
&#xD;
               -  Metastases evaluated by noninvasive methods&#xD;
&#xD;
          -  No evidence of active brain metastases&#xD;
&#xD;
               -  Prior brain metastases allowed provided all of the following criteria are met:&#xD;
&#xD;
                    -  Disease is stable&#xD;
&#xD;
                    -  Reductive therapy (surgery or radiotherapy) completed at least 3 weeks prior&#xD;
                       to study entry&#xD;
&#xD;
                    -  Metastases have not progressed (confirmed by CT scan or MRI)&#xD;
&#xD;
                    -  No concurrent corticosteroids required&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Creatinine &lt; 1.8 mg/dL&#xD;
&#xD;
          -  Hematocrit ≥ 30%&#xD;
&#xD;
          -  WBC ≥ 4,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 120,000/mm^3&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  LVEF ≥ 50%&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No HIV positivity&#xD;
&#xD;
          -  No severe infection requiring antibiotic therapy&#xD;
&#xD;
          -  No chronic hepatitis&#xD;
&#xD;
          -  No severe lung, liver or kidney condition that would preclude study treatment&#xD;
&#xD;
          -  No hepatitis B surface antigen positivity&#xD;
&#xD;
          -  No severe neuropsychiatric condition or epilepsy&#xD;
&#xD;
          -  No serious thromboembolitic disorder&#xD;
&#xD;
          -  No severe cardiac dysfunction (e.g., congestive heart failure, uncontrolled&#xD;
             hypertension, serious arrhythmia, or coronary disease)&#xD;
&#xD;
          -  No other prior or concurrent primary malignancies except for basal cell skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  No geographical, psychological, or familial condition that would preclude study&#xD;
             participation&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  More than 6 weeks since prior wide-field radiotherapy&#xD;
&#xD;
          -  No prior systemic chemotherapy&#xD;
&#xD;
          -  No prior organ transplantation&#xD;
&#xD;
          -  No prior cytokines&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
          -  No concurrent anticancer chemotherapy&#xD;
&#xD;
          -  No concurrent corticosteroids&#xD;
&#xD;
          -  No other concurrent immunotherapy&#xD;
&#xD;
          -  No other concurrent investigational agents or therapies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sylvie Negrier, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Leon Berard</affiliation>
  </overall_official>
  <results_reference>
    <citation>Negrier S, Perol D, Ravaud A, Chevreau C, Bay JO, Delva R, Sevin E, Caty A, Escudier B; French Immunotherapy Intergroup. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer. 2007 Dec 1;110(11):2468-77.</citation>
    <PMID>17932908</PMID>
  </results_reference>
  <verification_date>September 2012</verification_date>
  <study_first_submitted>December 27, 2006</study_first_submitted>
  <study_first_submitted_qc>December 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2006</study_first_posted>
  <last_update_submitted>September 25, 2012</last_update_submitted>
  <last_update_submitted_qc>September 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Aldesleukin</mesh_term>
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

